STAGREL-A & A75 Tablets
Diminishes the risk of cardiac insuffuciency
COMPOSITION:
- Stagrel-A: Clopidogrel 75 mg + Aspirin IP 150 mg
- Starel-A75: Clopidogrel 75 mg + Aspirin IP 75 mg
- Improves inflammatory responses, accelerates platelet function & blood coagulation system after coronary artery bypass grafting.
- Addition of clopidogrel decreases mortality rates by reducing the incidence of thrombotic vascular events in patients with congestive heart failure.
- Reduces the risk of stroke and also does not increase the risk of hemorrhage in patients with transient ischemic attack.
- Markedly inhibits (ADP)-mediated platelet aggregation and collagen-induced aggregation in patients with myocardial infarction.
INDICATIONS:
- Acute & chronic coronary syndrome
- Thromboembolic Stroke
- Recurrent Ischemic Stroke
- Myocardial Infarction
- Angina
- Atherosclerosis
Description
Clopidogrel
- Drug class: Antiplatelet medications
- Clopidogrel is a prodrug, which needs to be metabolized in the liver into active metabolites.
- Clopidogrel efficiently reduces ADP-induced platelet aggregation (a key phenomenon in atherosclerosis & CVD) and prolongs bleeding time and is a safe and efficacious antiplatelet drug
Aspirin
- Drug Class: NSAIDs
- The most widely tested antiplatelet regimen was aspirin.The benefit of low-dose aspirin therapy for the secondary prevention of serious cardiovascular events is clear.
- Aspirin has long been the therapeutic foundation of the secondary prevention of CVD, to which contemporary drugs such as statins, and other antithrombotics have been added.
Combination:
- Aspirin and clopidogrel are antiplatelet agents that display good antithrombotic activity.Clopidogrel in combination with aspirin is the current “gold standard” for reducing cardiovascular events.
- Clopidogrel plus aspirin can reduce the relative risk of adverse cardiovascular events by 20%, compared with aspirin alone.
